Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-like protein 2 (Alp2) is a key surface-anchored protein and virulence factor of Streptococcus agalactiae (Group B Streptococcus). It belongs to the Alpha-like protein family, which is defined by a mosaic structure consisting of a conserved N-terminal signal sequence and a series of large tandem repeats that facilitate bacterial adhesion to host epithelial cells. Alp2 is primarily expressed by GBS strains associated with invasive neonatal diseases, such as sepsis and meningitis, making it a critical target for diagnostic serotyping and therapeutic intervention. In the context of drug development, Alp2 is a primary antigen in recombinant protein-based vaccine candidates, where it elicits protective, opsonophagocytic antibodies. These vaccines aim to prevent maternal colonization and vertical transmission to newborns by neutralizing the bacteria's ability to adhere to and invade host tissues.
Vaccine-induced or therapeutic antibodies bind to the Alp2 protein on the bacterial surface, facilitating opsonophagocytic killing by host immune cells and preventing bacterial attachment to host tissues.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-like protein 2 (Alp2).